Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats

Cardiovascular Research

Volumn 44, Issue 3, 1999, Pages 543-548

  Makino, Naoki ^a   Sugano, Masahiro ^a   Ohtsuka, Shoji ^a   Sawada, Shojiro ^a   Hata, Tomoji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Blood pressure; Gene expression; Gene therapy; Hypertrophy; Remodelling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; ASIALOGLYCOPROTEIN; CARRIER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HISTOLOGY; HYPERTENSION; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANGIOTENSINOGEN; ANIMALS; CARDIOMEGALY; GENE EXPRESSION; GENE THERAPY; INJECTIONS, INTRAVENOUS; LIVER; MALE; MYOCARDIUM; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; VENTRICULAR REMODELING;

EID: 0033407633     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00254-0     Document Type: Article

References (37)

1. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1988;8:533-559.
2. Jeunemaitre X, Soubrier F, Kotelevetsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.
3. Kim HS, Krege JH, Kluckman KD et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995;92:2735-2739.
4. Caulfield M, Lavender P, Farrall M et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994;330:1629-1633.
5. Lynch KR, Peach MJ. Molecular biology of angiotensinogen. Hypertension 1991;17:263-269.
6. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992;54:227-241.
7. Sun Y, Ramires FJA, Zhou G, Ganjan VK, Weber KT. Fibrous tissue and angiotensin II. J Mol Cell Cardiol 1997;29:2001-2012.
8. 2+ modulation by angiotensin II and endothelin-1 in cardiomyocytes and fibroblasts from hypertrophied heart of spontaneously hypertensive rats. Hypertension 1996;28:797-805.
9. Unger T, Mattfeldt T, Lamberty V. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992;20:478-482.
10. Makino N, Sugano M, Ohtsuka S, Hata T. Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 1997;30:796-802.
11. Conrad CH, Brook WW, Hayes JA et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rats. Circulation 1995;91:161-170.
12. Gohlke P, Lamberty V, Kuwer I. Long-term low-dose angiotensin converting enzyme inhibition treatment increases vascular cyclic guanine 3′,5′-monophospate. Hypertension 1993;22:682-687.
13. Gohlke P, Linz W, Scholkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996;28:397-402.
14. Yoshida H, Kakuchi J, Guo DF et al. Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 1992;186:1042-1049.
15. Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous Injection with antisense oligodeoxynucleotides against angiotensinogen decreases both the blood pressure and plasma angiotensin II levels. Hypertension 1998;31:1166-1170.
16. Sugano M, Makino N. Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesterol ester transfer protein in cholesterol-fed rabbits. J Biol Chem 1996;271:19080-19083.
17. Wu GY, Wilson JM, Shalaby F et al. Receptor-mediated gene delivery in vivo. J Biol Chem 1991;266:14338-14342.
18. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 1961;35:1961-1965.
19. Hayakari M, Kondoh Y, Ihumi H. A rapid and simple spectro-photometric assay of angiotensin-converting enzyme. Anal Biochem 1978;84:361-369.
20. Takemoto E, Hasegawa Y, Katahira J, Nakao K, Inukai T. Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. Arzheim-Forsch/Drug Res 1991;41:612-615.
21. Kojima M, Shiojima I, Yamazaki T et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocytes hypertrophy in vitro. Circulation 1994;89:2204-2211.
22. Terada Y, Tomita K, Nonoguchi H, Marumo F. PCR localization of angiotensin II receptor and angiotensinogen mRNA in rat kidney. Kidney Int 1993;43:1251-1259.
23. Koike G, Krieger JE, Jacob HJ et al. Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNA and characterization of the enzyme. Biochem Biophys Res Commun 1994;198(1):380-386.
24. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (Lond) 1991;351:233-236.
25. Stoll M, Steckelings UM, Paul M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-653.
26. Fort PH, Marty I, Piechaczyk M et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 1985;13:1431-1442.
27. Chowdhury NR, Wu CH, Wu GY et al. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. J Biol Chem 1993;268:11265-11271.
28. Lu XM, Fischman AJ, Jyawook SL et al. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J Nucl Med 1994;35:269-275.
29. Lodwick D, Kaiser MA, Harris J et al. Analysis of the role of angiotensinogen in spontaneous hypertension. Hypertension 1995;25:1245-1251.
30. Tomita N, Morishita R, Higaki J et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995;26:131-136.
31. Wielbo D, Serina C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 1995;25:314-319.
32. Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 1996;28:147-151.
33. Tanimoto K, Sugiyama F, Goto Y et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994;269:31334-31337.
34. Kim S, Ohta K, Hamaguchi A et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995;273:509-515.
35. Korner PI, Bobik A. Cardiovascular development after enalapril in spontaneously hypertensive and Wistar-kyoto rats. Hypertension 1995;25(1):610-619.
36. Brilla CG, Janicki JS, Weber KT. Cardioprotective effects of lisinoprilin rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-1779.
37. Tomita N, Morishita R, Higaki J et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995;26:131-136.